Gilead Presents Real-World and Long-Term Data From HIV Research Programs at HIV Glasgow 2022 Pharmaceutical Investing
Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Tuberculosis Antibiotic Candidates Life Science Investing
Kite's Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma Pharmaceutical Investing
AbbVie Vice Chairman of External Affairs and Chief Legal Officer Laura J. Schumacher to Retire Pharmaceutical Investing
Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies Pharmaceutical Investing
Gilead Sciences to Release Third Quarter 2022 Financial Results on Thursday, October 27, 2022 Pharmaceutical Investing
Lobe Sciences Announces the Completion of cGMP Production of Clinical Supplies For Upcoming Clinical Trials Pharmaceutical Investing
For World Sight Day, new app available for Canadians living with glaucoma, the Silent Thief of Sight Pharmaceutical Investing
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older Life Science Investing
